Famous Patents
3M employee and church chorister Art Fry needed something to temporarily mark pages in his hymnal. He was in luck because his colleague, Spencer Silver, accidentally developed a glue that was too weak for other purposes. After initially discouraging consumer response, Post-it Notes became a hit in 1979.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 6664290 | Oral or vaginal administration of mesoprostol in third stage labor This invention relates to a method of limiting postpartum hemorrhage comprising administering orally a single effective dose of misoprostol to a woman during the third stage of labor.... | 12/16/2003 |
| 6586021 | Method for extraction and purification of biologically useful molecules from a mangrove plant Salvadora persica L The invention discloses a process of extracting, fractionating and purifying bioactive molecules from an associated mangrove plant, methods of screening for pharmacological activities of the crude extract, fractions, and purified compounds.... | 07/01/2003 |
| 6428823 | Biologically active aqueous fraction of an extract obtained from a mangrove plant Salvadora persica L The invention discloses a process of extracting, fractionating and purifying bioactive molecules from an associated mangrove plant, methods of screening for pharmacological activities of crude extract, it fractions and purified compounds and the use of th... | 08/06/2002 |
| 6306899 | Inhibition and treatment of Hepatitis B virus and Flavivirus by Helioxanthin and its analogs This invention relates to anti-viral drugs such as Helioxanthin and its analogs. The present compounds may be used alone or in combination with other drugs for the treatment of Hepatitis B virus (HBV), Hepatitis C virus (HCV), Yellow Fever, Dengue Virus, ... | 10/23/2001 |
| 6271201 | Methods for the selective regulation of placental prostanoids and inhibition of labor using IGF-I Methods for inhibiting the production of specific vasoconstrictive prostanoids, such as thromboxane and prostaglandin F2, through the addition of insulin like growth factor, particularly IGF-I or IGF-II, to human placental cells are disc... | 08/07/2001 |
| 6162833 | Photostable aqueous solution comprising benzyl alcohol derivatives Aqueous solution, including at least one of optically active (-)-(R)--((tert-butylamino)methyl)-2-chloro-4-hydroxybenzyl alcohol represented by the following formula: ##STR1## and pharmacologically acceptable salt thereof. The aqueous solution... | 12/19/2000 |
| 5952387 | Photostable aqueous solution containing benzyl alcohol derivatives Aqueous solution, including at least one of optically active (-)-(R)--((tert-butylamino)methyl)-2-chloro-4-hydroxybenzyl alcohol represented by the following formula: ##STR1## and pharmacologically acceptable salt thereof. The aqueous solution... | 09/14/1999 |
| 5744464 | Antigestagens for the inhibition of uterine synthesis of prostaglandin Antigestagens inhibit prostaglandin synthesis by the uterus and thus can be used to treat symptoms of dysmennhorea.... | 04/28/1998 |
| 5731347 | Method of treating small mouth ulcers The present invention relates to the surprising and unexpected discovery that a simple alpha hydroxy organic acid, for example, lactic acid, glycolic acid or any of their pharmaceutically compatible salts, may be used in a therapy for treating aphthous ul... | 03/24/1998 |
| 5708036 | Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol The optically pure R-isomer of the adrenergic beta-2 agonist albuterol, substantially free of its corresponding S-isomer, has been found to potently inhibit premature uterine contractions in female subjects, suffering from said condition, while avoiding s... | 01/13/1998 |
| 5656297 | Modulated release from biocompatible polymers The present invention relates to a composition for the modulated release of a biologically active agent. The composition comprises a biocompatible polymeric matrix, a biologically active agent which is dispersed within the polymeric matrix, and a metal ca... | 08/12/1997 |
| 5595980 | Contraceptive compositions Improved contraceptive compositions are disclosed which comprise a spermicide or virucide, a polymeric delivery component and optionally a cosmetic ingredient. The improvement is directed to the use of certain hydrophobically modified polysaccharides as t... | 01/21/1997 |
| 5583105 | Oral pharmaceutical preparation The invention relates to an oral multiple emulsion pre concentrate comprising a surface active agent, ethanol a lipophilic and/or an amphiphilic solvent. The composition comprising from about 5 to about 30% by weight of cyclosporin, from about 5 to about ... | 12/10/1996 |
| 5529993 | 14, 17-ethano-16-hydroxy-estratrienes A 14,17-bridged estratriene of formula I ##STR1## wherein (a) OR3 is in -position R1, R2 and R3, each independently are (i) hydrogen, (ii) ##STR2## in which R4 is an organic... | 06/25/1996 |
| 5518716 | Composition and method of preparing microemulsion blends A microemulsion composition comprising a microemulsifiable silicone and a volatile silicone, the microemulsion formed therewith, a means for preparing said microemulsion, and personal care products comprising said microemulsion.... | 05/21/1996 |
| 5504116 | Lidocaine for the management of preterm labor The use of lidocaine or other Class I cardiac antiarrhythmic compound in the management of preterm labor and the stoppage of labor preparatory to cesarian delivery, is disclosed. The electrophysiological effects of lidocaine on the sodium, calcium and pot... | 04/02/1996 |
| 5409955 | Compositions and methods for inhibiting uterine contractility There is disclosed a composition for inhibiting uterine contractility by topical or local administration. The composition contains an omega fatty acid in combination with a cyclo-oxygenase inhibitor. Preferred omega fatty acids include docosahexaenoic aci... | 04/25/1995 |
| 5356904 | Carbostyril oxytocin receptor antagonists A method of inhibiting oxytocin from acting at its receptor site by administering oxytocin receptor antagonist compounds of the formula ##STR1## wherein X is oxygen or sulfur; Y is hydrogen or lower alkyl; RA is ##STR2##... | 10/18/1994 |
| 5246704 | Vaginal suppository Disclosed is a vaginal suppository comprising a pharmaceutically acceptable salt of dehydroepiandrosterone sulfate (hereinafter referred to as DHAS), an amino acid and a hard fat having a hydroxy value of not more than 50. This suppository features an imp... | 09/21/1993 |
| 5198463 | Oxytocin antagonists A method for inhibiting oxytocin activity by administering an oxytocin inhibiting amount of a penicillide compound having the formula ##STR1## and compositions for such use are described.... | 03/30/1993 |
| 5116619 | Vaginal progesterone tablet A vaginal progesterone suppository is provided in the form of a tablet which delivers biologically effective amounts of progesterone for at least about 48 hours, and blood amounts above basal levels for 72 hours. The tablet is formulated to preferably hav... | 05/26/1992 |
| 5095010 | Antigestagens, glucocorticoids and prostaglandins for induction of labor or for termination of pregnancy Combination products containing an antigestagen, a glucocorticoid and a prostaglandin are suitable for combined use in inducing labor or terminating pregnancy.... | 03/10/1992 |
| 5036107 | 1,7-substituted heptyn-2-ones and use 1-Phenyl-7-substituted-hept-5-yn-2-ones substituted with a C1 to C7 alkyl, C3 to C6 cycloalkyl, aryl, heteroaryl or heterocycloalkyl group at the 1-position and an amino, a dialkylamino, a piperidyl, a pyrrolidy... | 07/30/1991 |
| 5036056 | Methods for treating damaged corneal, uterine, or cartilage tissue Methods for treating damaged corneal, uterine or cartilage tissue comprising applying a therapeutically effective amount of a composition comprising: (a) a sterile extracellular connective tissue matrix composition comprising collagens, proteoglycans, gly... | 07/30/1991 |
| 5011688 | Liquid composition for the relief of premenstrual and menstrual discomforts A liquid composition for the relief of premenstrual and menstrual discomfort comprising, as active pharmaceutical agents, an effective amount of an analgesic, an antihistamine, and a diuretic, said active agents being dissolved in a liquid vehicle, said c... | 04/30/1991 |
| 4945082 | Controlled dsRNA therapy for human viral infections The rate of viral dysfunction of subject's immune response in the rate of progression of HIV or like virus from seropositive LAS Pre-ARC ARC frank AIDS is tracked and antiviral therapy based upon dsRNA is initiated and regulated using clinical measurement... | 07/31/1990 |
| 4870067 | Oxytocins and antigestagens in combination for induction of birth A combination product contains oxytocin and/or an oxytocin analog and an antigestagen for induction of birth.... | 09/26/1989 |
| 4795744 | Modulation of AIDS virus-related events by double-stranded RNAS The use of mismatched dsRNA, e.g. Ampligen for the manufacture of compositions for use in the selective activation of a latent natural defense system within human cells, both cells already infected with AIDS virus as well as cells at risk to infection. Sp... | 01/03/1989 |
| 4789669 | Vaginal suppository A vaginal suppository comprising a pharmaceutically acceptable salt of dehydroepiandrosterone sulfate and a hard fat with a hydroxyl value not exceeding 50. This vaginal suppository is useful for improving the ante-partum condition of pregnant women and f... | 12/06/1988 |
| 4499293 | PGI2 Salts Prostaglandin (PG1) derivatives having a 5,6-didehydro feature, for example an enol ether of the formula ##STR1## said derivatives having pharmacological activity. Processes for preparing them and the appropriate intermediates are disclose... | 02/12/1985 |
| 4483794 | Analogs of neurohypophysial hormones Analogs of neurohypophysial hormones with inhibition properties are described. The hormones are of the formula ##STR1## wherein in all chiral amino acids are of the L-series and the aromatic amino acid in the position 2, indicated with an asterisk, i... | 11/20/1984 |
| 4342868 | 2-Descarboxy-2-(tetrazol-5-yl)-16,16-dimethyl-17-( 2-furyl)-ω-trisnorprostaglandin E2 15-Substituted-ω-pentanorprostaglandin C-1 tetrazoles, imides and sulfonimides. Their use as anti-secretory agents or as agents for the control of fertility.... | 08/03/1982 |
| 4152527 | 15-Substituted-ω-pentanorprostaglandins The 15-substituted-ω-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater tissu... | 05/01/1979 |
| 4066787 | Stabilized prostaglandin composition and the process for the preparation thereof A dried and stabilized prostaglandin composition containing a prostaglandin E group compound with calcium lactate and/or amylopectin, and a stabilized pharmaceutical preparation for practical administration prepared from the said composition.... | 01/03/1978 |
| 4054736 | Clathrate compounds of prostaglandins or their analogues with cyclodextrin Clathrate compounds of prostaglandins or their analogues with cyclodextrins and a method of manufacture thereof. The compounds are useful as labor inducing agents, contraceptives, hypotensives and remedies for ulcers and asthma.... | 10/18/1977 |
| 4035373 | Preparation of piperidinyl-alkyl-benzamides New piperidinyl-alkyl-benzamides and salts thereof are disclosed, together with a method for the production of the benzamides and salts. The benzamides, which have beta-adrenergic agonist effects, have the general formula ##STR1## The hydrochlor... | 07/12/1977 |
| 4035415 | Omega-nor-cycloalkyl-13,14-dehydro-prostaglandins Omega-nor-cycloalkyl-13,14-dehydro-prostaglandin compounds, specifically 13,14-dehydro-17-cyclohexyl-20,19,18-trinor-PGF2.sub., having selective luteolytic, abortifacient and labor-inducing activity and extremely low untoward gastrointes... | 07/12/1977 |
| 3974213 | 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins The 15 aryl substituted-ω-pentanorprostaglandins and various intermediates employed in their preparation. The novel prostaglandins of this invention have been found to have activity profiles comparable to the parent prostaglandins, but exhibit a greater ... | 08/10/1976 |
| 3940438 | Crystalline racemic 9,11,15(S)-trihydroxy-5-cis,13-trans-prostadienoic acid The invention concerns a novel crystalline racemate, 9,11,15(S)-trihydroxy-5-cis,13-trans-prostadienoic acid. The racemate can be administered in pharmaceutical dosage forms or from a drug delivery device at a programmed rate for producing s... | 02/24/1976 |
